We asked: Vimentin peptide strategy
Co-fold the target with the ligand to test complex formation + affinity.
Cross-species caveat. Co-folded against human 4JPS (PI3Kα / p110α). The canine PIK3CA ortholog (UniProt A0A5F4C2B1 / RefSeq XP_545208.2, taxid 9615) is 99.8% identical to human overall and 100% identical at every alpelisib/ATP-pocket residue — and a redock-verified canine receptor (AlphaFold AF-A0A5F4C2B1, alpelisib redock 0.62 Å) is now in the library — so the human structure is a justified cross-species proxy (the binding pocket is sequence-identical), not an unverified substitution.
Pre-registered tests, each locked to a kill-criterion before it ran. Any single one failing rules the whole idea out.
A pre-registered test disproved it. Being wrong fast, on purpose, is a win.
Readout. Boltz-2 co-folded ethanol with PIK3CA: interface iptm 0.25, P(binder)=0.05, affinity_pred 1.85 (log µM, lower=stronger). Signal: refutes.
Confidence so far: 0% — never proof.
Every result is hashed so anyone can re-derive it. Clearing these checks is necessary, not sufficient — a human still holds the final call, and nothing is auto-promoted.
See the full experiment record.
The pre-registered kill-criterion, the raw readout, and the signed provenance you can verify yourself — plus every new verdict as it lands. Drop your email and we’ll open it up.
A mailing list for early access, not a login. We’ll email you to set up real sign-in once things are polished.